Evidence that folic acid deficiency is a major determinant of hyperhomocysteinemia in Parkinson´s disease
| Autor: | Jaderson Costa da Costa, Jonas Alex Morales Saute, Eliseu Felippe dos Santos, Anelise Miglioranza, Alethea Gatto Barchak, Estela Natacha Brandt Busanello, Maria Julia M. Carrion, Charles Rosa, Moacir Wajner, Daiane Piccolotto Carvalho Camargo, Carmen Regla Vargas, Ângela Zanatta, André Dalbem, Sandro René Pinto de Sousa Miguel, Carlos Roberto de Mello Rieder |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Male
medicine.medical_specialty Levodopa Hyperhomocysteinemia Neurology Parkinson's disease Homocysteine Matched-Pair Analysis Folic Acid Deficiency Biochemistry Statistics Nonparametric Cellular and Molecular Neuroscience chemistry.chemical_compound Folic Acid Reference Values Internal medicine medicine Humans Vitamin B12 Analysis of Variance Chemistry Case-control study Parkinson Disease Middle Aged medicine.disease Vitamin B 12 Endocrinology Case-Control Studies Nerve Degeneration Female Neurology (clinical) Analysis of variance medicine.drug |
| Zdroj: | Metabolic Brain Disease. 24:257-269 |
| ISSN: | 1573-7365 0885-7490 |
| DOI: | 10.1007/s11011-009-9139-4 |
| Popis: | In the present work we measured blood levels of total homocysteine ((t)Hcy), vitamin B(12) and folic acid in patients with Parkinson s disease (PD) and in age-matched controls and searched for possible associations between these levels with smoking, alcohol consumption, L-DOPA treatment and disease duration in PD patients. We initially observed that plasma (t)Hcy levels were increased by around 30 % in patients affected by PD compared to controls. Linear correlation, multiple regression and comparative analyses revealed that the major determinant of the increased plasma concentrations of (t)Hcy in PD patients was folic acid deficiency, whereas in controls (t)Hcy levels were mainly determined by plasma vitamin B(12) concentrations. We also observed that alcohol consumption, gender and L-DOPA treatment did not significantly alter plasma (t)Hcy, folic acid and vitamin B(12) levels in parkinsonians. Furthermore, disease duration was positively associated with (t)Hcy levels and smoking was linked with a deficit of folic acid in PD patients. Considering the potential synergistic deleterious effects of Hcy increase and folate deficiency on the central nervous system, we postulate that folic acid should be supplemented to patients affected by PD in order to normalize blood Hcy and folate levels, therefore potentially avoiding these risk factors for neurologic deterioration in this disorder. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink